...
首页> 外文期刊>Scandinavian journal of immunology. >Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.
【24h】

Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia.

机译:卵巢肿瘤患者外周血单个核细胞中CD56 + NK和NKT样淋巴细胞的离体扩增。

获取原文
获取原文并翻译 | 示例

摘要

Methods for ex vivo expansion of natural killer (NK) cells have allowed obtaining enough numbers of human NK cells for clinical trials. However, the evaluation of these methods has been mostly limited to haematological malignancies. This study aimed at evaluating a method for selective expansion of NK cells when applied in peripheral blood mononuclear cells (PBMC) of patients with ovarian neoplasia. PBMC from 13 volunteer patients with ovarian neoplasia, seven benign and six malignant tumours, were cultured in CellGro medium supplemented with anti-CD3 (9-10 initial days), IL-2 and foetal bovine serum for 21 days. The resulting effector cells were evaluated for their phenotype, cytotoxicity and cytokine secretion. PBMC cultures resulted in multiple populations (NK, NKT and T) of effector cells, enriched with CD56(+) lymphocytes. NK cells from patients with benign and malignant ovarian neoplasia were expanded 139.6 +/- 63.4 and 82.7 +/- 25.3-fold, respectively, being the largest lymphocyte subtype among CD56(+) population. Effector cells expanded from patients with malignant ovarian neoplasia had higher proportion of T lymphocytes and altered cytokine production patterns, characterized by lower INF-gamma, TNF-alpha and higher IL-4, compared with patients with benign ovarian neoplasia. Effector cells were cytotoxic against K562 and OVCAR3 cell lines. Cytotoxicity was significantly higher (P < 0.05) using magnetically separated CD56(+) effector cell fractions compared with CD56-deprived ones. The present study demonstrates the feasibility of the culture system employed to generate effector cells, enriched with CD56(+) lymphocytes, from PBMC of patients with ovarian neoplasia. NK cells were the largest lymphocyte subtype among the CD56(+) population and the main variable among the final effector cell preparation affecting target cell killing.
机译:用于自然杀伤(NK)细胞的离体扩增的方法已允许获得足够数量的人NK细胞用于临床试验。但是,对这些方法的评估主要限于血液系统恶性肿瘤。这项研究旨在评估一种应用于卵巢肿瘤患者外周血单个核细胞(PBMC)时NK细胞选择性扩增的方法。在补充了抗CD3(最初的9-10天),IL-2和胎牛血清的CellGro培养基中培养了13名自愿性卵巢肿瘤,七个良性和六个恶性肿瘤患者的PBMC 21天。评价所得的效应细胞的表型,细胞毒性和细胞因子分泌。 PBMC文化导致效应细胞的多个种群(NK,NKT和T),其中富含CD56(+)淋巴细胞。来自患有良性和恶性卵巢肿瘤的患者的NK细胞分别扩展了139.6 +/- 63.4和82.7 +/- 25.3倍,是CD56(+)人群中最大的淋巴细胞亚型。与卵巢良性肿瘤患者相比,恶性卵巢肿瘤患者产生的效应细胞具有更高的T淋巴细胞比例和细胞因子产生模式的改变,其特征在于INF-γ,TNF-α和IL-4水平较低。效应细胞对K562和OVCAR3细胞系具有细胞毒性。磁性分离的CD56(+)效应细胞部分与CD56剥夺的相比,细胞毒性显着更高(P <0.05)。本研究证明了用于从卵巢肿瘤患者的PBMC中生成富含CD56(+)淋巴细胞的效应细胞的培养系统的可行性。 NK细胞是CD56(+)人群中最大的淋巴细胞亚型,并且是影响靶细胞杀死的最终效应细胞制备中的主要变量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号